A Quantitative Study of Bone Marrow Grafting: Implications for Human Bone Marrow Infusion

Journal Article · Sat Sep 01 04:00:00 EDT 1962 · British Journal of Cancer

DOI:https://doi.org/10.1038/bjc.1962.46· OSTI ID:4743991

Pegg, D. E.

Radiation survival curve data and total bone marrow cellularity measurements in experimental animals and man are reviewed. On the basis of total bone marrow cellularity and the minimum effective marrow infusion in animal experiments it is concluded that a 70 kg man would require 0.7 to 5.2 x 10⁹ autologous marrow cells or 9 to 13 x 10⁹ homologous marrow cells after lethal whole-body irradiation. Bone marrow protection is far less effective after lethal doses of radiomimetic chemotherapeutic agents. When the numbers of marrow cells calculated to survive various doses of whole-body irradiation are calculated and compared with the amount of marrow infused in successful isologous marrow grafting experiments, it is found that numerical comparison gives unacceptable results; reasons for this anomaly are suggested which avoid the proposition that marrow cells have an intrinsic radiosensitivity different from that of other somatic cells. The practical care of the patient who has received large doses of whole-body irradiation or radiomimetic chemotherapy is considered. The potency of autologous marrow infusion and the dangers of homologous marrow infusion are emphasized and the place of antibiotics, platelet, and whole blood treatment is discussed.

• Research Organization: Westminster Hospital and Medical School, London
• Sponsoring Organization: USDOE
• NSA Number: NSA-17-007820
• OSTI ID: 4743991
• Journal Information: British Journal of Cancer, Journal Name: British Journal of Cancer Journal Issue: 3 Vol. 16; ISSN 0007-0920
• Country of Publication: Country unknown/Code not available
• Language: English

Related Subjects

ANIMAL CELLS
ANIMALS
BIOLOGY AND MEDICINE
BLOOD CELLS
BODY
BONE MARROW
CHEMICALS
IRRADIATION
LETHAL DOSE
LIFETIME
MAN
PLATELETS
QUANTITY RATIO
RADIATION PROTECTION
RADIOMIMETIC DRUGS
RADIOSENSITIVITY
TRANSFUSIONS
TRANSPLANTS